Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This protocol describes optimization procedures in a virus-based dual fluorescence-labeled tumor xenograft model using larval zebrafish as hosts. This heterogeneous xenograft model mimics the tissue composition of pancreatic cancer microenvironment in vivo and serves as a more precise tool for assessing drug responses in personalized zPDX (zebrafish patient-derived xenograft) models.

Abstract

Patient-derived tumor xenograft (PDX) and cell-derived tumor xenograft (CDX) are important techniques for preclinical assessment, medication guidance and basic cancer researches. Generations of PDX models in traditional host mice are time-consuming and only working for a small proportion of samples. Recently, zebrafish PDX (zPDX) has emerged as a unique host system, with the characteristics of small-scale and high efficiency. Here, we describe an optimized methodology for generating a dual fluorescence-labeled tumor xenograft model for comparative chemotherapy assessment in zPDX models. Tumor cells and fibroblasts were enriched from freshly-harvested or frozen pancreatic cancer tissue at different culture conditions. Both cell groups were labeled by lentivirus expressing green or red fluorescent proteins, as well as an anti-apoptosis gene BCL2L1. The transfected cells were pre-mixed and co-injected into the 2 dpf larval zebrafish that were then bred in modified E3 medium at 32 °C. The xenograft models were treated by chemotherapy drugs and/or BCL2L1 inhibitor, and the viabilities of both tumor cells and fibroblasts were investigated simultaneously. In summary, this protocol allows researchers to quickly generate a large amount of zPDX models with a heterogeneous tumor microenvironment and provides a longer observation window and a more precise quantitation in assessing the efficiency of drug candidates.

Introduction

Precision oncology aims to find the most beneficial therapeutic strategies for individual patient1. Currently, numerous preclinical models such as in vitro primary culture, in vitro organoid culture2, and patient-derived xenografts (PDX) in mice before or after organoid culture are proposed for diagnosis and to screen/assess the potential therapeutic choices3. PDX model generated by the injection of human primary cancer cells into immune-compromised mice, is one of the most promising tools for personalized drug screening in clinical oncology3,4<....

Protocol

All animal procedures were approved and followed the guidelines of the Animal Ethics Committee at Fudan University and all pancreatic cancer specimens were obtained from Fudan University Shanghai Cancer Center. Ethical approval was obtained from the FUSCC Ethics Committee, and written informed consent was obtained from each patient.

1. Preparing the Equipment for the Microinjection

  1. Preparing the injection plate.
    1. Prepare a 50 mL solution of 1% agarose di.......

Representative Results

A schematized outline of the procedure is represented in Figure 1. In short, the primary cancer tissue cells were seeded into the complete medium after digestion with or without the addition of pancreatic cancer fibroblast inhibitors. Cancer cells and fibroblasts were enriched as two distinct populations that fibroblasts dominated without inhibitors, and cancer cell growth prevailed after the addition of inhibitors (Figure 2). Tw.......

Discussion

Both PDX and CDX models are vital platforms in the field of tumor biology22, and the critical step of a successful inter-species transplantation is to improve the survival of the xenograft.  Recently, some studies have shown that transient expression of BCL2L1 (BCL-XL) or BCL2 may significantly improve the viability of human embryonic stem cells in mice hosts without affecting the cell identities and fates23,24

Acknowledgements

This work was supported by National Natural Science Foundation of China 81402582, Natural Science Foundation of Shanghai 12DZ2295100, 14YF1400600 and 18ZR1404500

....

Materials

NameCompanyCatalog NumberComments
DMEMGIBCOC11995500BT
FBSHyclonesv30087.03
Y-27632CliniscienceY0503Rho kinase inhibitor
Primocininvivogenant-pm-1an antibiotic for primary cell cultures
Putrescine dihydrochlorideSigmaP5780
Nicotinamide SigmaN3376
penicillin streptomycinGIBCO15140122.00
phosphate buffer (PBS)GIBCOC10010500CP
HBSS GIBCO14170112.00
collagenase type IVGIBCO17104019.00
hyaluronidaseSigmaH3884
DnaseⅠSigmaD5025
insulinSigmaI9278
b-FGFGIBCOPHG0264
EGFGIBCOPHG0314
pancreatic cancer fibroblasts inhibitorCHI ScientificFibrOUT
0.45 μm sterile filterMilliporeSLHV033RB
concentration columnMilliporeMillipore UFC910008Concentrate the virus
polybrene SigmaH9268
Hyaluronic Acid Sodium SaltSigmaH7630
L-glutamineGIBCO21051024.00
gemcitabineGemzan
methylcelluloseSigmaM0262
Navitoclax(ABT-263)SelleckS1001Bcl-xL inhibitor
Equipment
MicroinjectorNARISHIGE
stereomicroscopeOLYMPUSMVX10
Confocal MicroscopeLEICASP80.00

References

  1. Collins, D. C., Sundar, R., Lim, J. S. J., Yap, T. A. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends in Pharmacological Sciences. 38 (1), 25-40 (2017).
  2. Huang, L., et al.

Explore More Articles

Zebrafish LarvaePDX ModelPancreatic CancerDrug AssessmentFluorescent LabelingCell SurvivalPersonalized MedicineXenograftIn Vivo TracingTissue DissociationCell Preparation

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved